O-1918是一種人工合成的有機化合物,分子式C19H26O2,化學結構上與大麻二酚相似,可作為前孤兒受體G蛋白偶聯受體GPR18GPR55受體拮抗劑[1][2][3][4][5]

O-1918
識別資訊
  • 1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene
CAS號536697-79-7  checkY
PubChem CID
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C19H26O2
摩爾質量286.19
3D模型(JSmol英語JSmol
  • CC1=C[C@@H](C2=C(OC)C=C(C)C=C2OC)[C@H](C(C)=C)CC1

參考文獻

編輯
  1. ^ Offertáler L, Mo FM, Bátkai S, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology. March 2003, 63 (3): 699–705. PMID 12606780. doi:10.1124/mol.63.3.699. 
  2. ^ Zakrzeska A, Schlicker E, Baranowska M, et al. A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats. British Journal of Pharmacology. June 2010, 160 (3): 574–84. PMC 2931558 . PMID 20105178. doi:10.1111/j.1476-5381.2009.00579.x. 
  3. ^ Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neuroscience Letters. August 2011, 500 (1): 72–6. PMID 21683763. S2CID 3410391. doi:10.1016/j.neulet.2011.06.004. 
  4. ^ Szczesniak AM, Maor Y, Robertson H, et al. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. Journal of Ocular Pharmacology and Therapeutics. October 2011, 27 (5): 427–35. PMID 21770780. doi:10.1089/jop.2011.0041. 
  5. ^ Caldwell MD, Hu SS, Viswanathan S, et al. A GPR18-based signalling system regulates IOP in murine eye. British Journal of Pharmacology. June 2013, 169 (4): 834–43. PMC 3687663 . PMID 23461720. doi:10.1111/bph.12136. 

外部連結

編輯